AM Arm (n=16) | M Arm (n=15) | p Value (AM vs M arm) | All patients (N=31) | |
---|---|---|---|---|
Age (years, median (IQR)) | 56 (38.8–62) | 64 (59–66) | 0.02 | 61 (53–65) |
Sex (male/female (female)) | 10/16 (62.5%) | 10/15 (66.7%) | 0.56 | 20/31 (64.5%) |
Disease duration (years, median (IQR)) | 7.6 (4.0–12.1) | 10.4 (5.2–19.2) | 0.45 | 8.0 (4.8–16.2) |
Time (months) on ADA at baseline (median (IQR)) | 26.5 (12.5–51.2) | 43.3 (11.7–51.5) | 0.19 | 29.1 (12.3–51.2) |
Time from RA diagnosis to ADA start (years, median (IQR)) | 3.2 (2.2–9.5) | 6.5 (4.1–15.1) | 0.63 | 4.8 (2.8–10.4) |
RF (positive) | 11/16 (68.8%) | 11/12 (91.7%) | 0.16 | 22/28 (78.6%) |
Anti-CCP (positive) | 5/10 (50%) | 8/9 (88.9%) | 0.09 | 13/19 (68.4%) |
Number of previous DMARDs (median (IQR)) | 2 (1–3) | 2 (2–3) | 0.99 | 2 (1–3) |
Number of previous biologics (median (IQR)) | 0 (0–1) | 0 (0–1) | 0.83 | 0 (0–1) |
Baseline DAS28 (median (IQR)) | 2.13 (1.6–2.4) | 1.69 (1.5–2.37) | 0.45 | 1.9 (1.55–2.39) |
Baseline HAQ (median (IQR)) | 0.13 (0–0.72) | 0.38 (0.13–0.63) | 0.47 | 0.38 (0–0.63) |
Concomitant MTX dose (median (IQR)) | 20 (15–20) | 20 (10–20) | 0.55 | 20 (15–20) |
ADA, adalimumab; anti-CCP, anticyclic citrullinated peptide antibodies; DAS28, Disease Activity Score based on 28 joints; DMARD, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor.